Format

Send to

Choose Destination
Health Policy. 2015 Jul;119(7):964-79. doi: 10.1016/j.healthpol.2014.12.016. Epub 2014 Dec 30.

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence.

Author information

1
Medical Technology Research Group, LSE Health, London School of Economics and Political Science, Houghton Street, WC2A 2AE London, United Kingdom. Electronic address: a.n.angelis@lse.ac.uk.
2
Medical Technology Research Group, LSE Health, London School of Economics and Political Science, Houghton Street, WC2A 2AE London, United Kingdom.

Abstract

Cost-of-illness studies, the systematic quantification of the economic burden of diseases on the individual and on society, help illustrate direct budgetary consequences of diseases in the health system and indirect costs associated with patient or carer productivity losses. In the context of the BURQOL-RD project ("Social Economic Burden and Health-Related Quality of Life in patients with Rare Diseases in Europe") we studied the evidence on direct and indirect costs for 10 rare diseases (Cystic Fibrosis [CF], Duchenne Muscular Dystrophy [DMD], Fragile X Syndrome [FXS], Haemophilia, Juvenile Idiopathic Arthritis [JIA], Mucopolysaccharidosis [MPS], Scleroderma [SCL], Prader-Willi Syndrome [PWS], Histiocytosis [HIS] and Epidermolysis Bullosa [EB]). A systematic literature review of cost of illness studies was conducted using a keyword strategy in combination with the names of the 10 selected rare diseases. Available disease prevalence in Europe was found to range between 1 and 2 per 100,000 population (PWS, a sub-type of Histiocytosis, and EB) up to 42 per 100,000 population (Scleroderma). Overall, cost evidence on rare diseases appears to be very scarce (a total of 77 studies were identified across all diseases), with CF (n=29) and Haemophilia (n=22) being relatively well studied, compared to the other conditions, where very limited cost of illness information was available. In terms of data availability, total lifetime cost figures were found only across four diseases, and total annual costs (including indirect costs) across five diseases. Overall, data availability was found to correlate with the existence of a pharmaceutical treatment and indirect costs tended to account for a significant proportion of total costs. Although methodological variations prevent any detailed comparison between conditions and based on the evidence available, most of the rare diseases examined are associated with significant economic burden, both direct and indirect.

KEYWORDS:

BURQoL-RD; Cost of illness; Orphan drugs; Rare diseases; Socioeconomic impact; Systematic review

PMID:
25661982
DOI:
10.1016/j.healthpol.2014.12.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center